Betamethasone diproprionate emollient spray (Sernivo, Promius Pharma) appears to have modest efficacy, similar to generic betamethasone diproprionate, says Dr. Han. In a 351-patient randomized clinical trial, 19% of patients met the endpoint of IGA zero or one, including a twopoint improvement from baseline, vs. 2.3% for placebo.9 However, the spray showed good tolerability—13.6% of patients who used a betamethasone lotion comparator experienced burning/stinging, versus 4.1% with the spray (P = 0.006).
Additionally, a calcipotriene-betamethasone cream formulation (MC2-01, MC2 Therapeutics) that has completed phase three psoriasis trials offers a novel vehicle that is says to improve drug delivery partly through a novel oil-in-water dispersion that results in a cosmetically elegant vehicle. MC2 Therapeutics is expected to file a new drug application this year.
Dr. Han has been an advisor for Intraderm, Janssen, UCB and Eli Lilly; an investigator for MC2 Therapeutics; a speaker for Sun Pharma; an investigator and speaker for Pfizer; and an advisor and speaker for Sanofi Regeneron.
George Han MD. “New and Upcoming Topicals in Psoriasis and Atopic Dermatitis,” Atlantic Dermatological Conference. May 5, 2019. New York.
1. Bissonnette R, Poulin Y, Zhou Y, et al. Effi cacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol.2012;166:853-860.
2. Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol.2017;137:2110-2119.
3. Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80:89-98.e3.
4. Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178:424-432.
5. Stein Gold L, Lebwohl M, Menter A, Villumsen J, Rosen M, Koo J. Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J Drugs Dermatol. 2016;15:951-957.
6. Kim ES, Frampton JE. Calcipotriol/betamethasone dipropionate foam: a review in plaque psoriasis. Drugs. 2016;76:1485-1492.
7. Lebwohl MG, Sugarman JL, Gold LS, et al. Long-term safety results from a phase 3 open-label study of a fi xed combination halobetasolpropionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80:282-285.
8. Kerdel FA, Draelos ZD, Tyring SK, Lin T, Pillai R. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis. J Dermatolog Treat.2019;30:333-339.
9. Fowler JF Jr, Hebert AA, Sugarman J. DFD-01, a novel medium potency betamethasone dipropionate 0.05% emollient spray, demonstrates similar efficacy to augmented betamethasone dipropionate 0.05% lotion for the treatment of moderate plaque psoriasis. J Drugs Dermatol. 2016;15:154-162.